Duke scientist's cancer research is questioned

Jul 23, 2010 By MARILYNN MARCHIONE , AP Medical Writer

(AP) -- Concerns are being raised about the validity of research done by a Duke University cancer scientist who recently was placed on leave while the school investigates whether he falsely claimed to be a Rhodes scholar.

The editor of a British journal, Lancet Oncology, issued an "expression of concern" Friday about a 2007 study by Duke's Dr. Anil Potti. It described that may help predict who most needs .

The journal says that some of Potti's co-authors contacted them this week with concerns about the report, which the medical journal is now investigating. Neither the scientist nor Duke officials could immediately be reached for comment.

Explore further: New breast cancer screening analysis confirms biennial interval optimal for average risk women

0 shares

Related Stories

Spat between medical journals in England

Mar 16, 2007

A British medical publication has called on researchers to boycott another British medical journal, the Lancet, over its parent company's "warmongering."

Genomic signature of colon cancer may individualize treatment

Nov 24, 2008

Researchers in the Duke Institute for Genome Sciences & Policy have developed a model for predicting risk of recurrence in early stage colon cancer patients, and have used the model to also predict sensitivity to chemotherapy ...

When Genes Cooperate, Lung Cancer Grows and Spreads

Mar 09, 2009

(PhysOrg.com) -- The combined expression of three specific genes in lung cancer tumors may predict both cancer growth and a poorer prognosis, according to a study led by researchers in the Duke Institute for Genome Sciences ...

Recommended for you

HLA expression tied to penile cancer outcomes

4 hours ago

(HealthDay)—Human leukocyte antigen (HLA) expression appears to be tied to clinical outcomes in penile cancer, according to a study published in the April issue of The Journal of Urology.

Study points to potential new lung cancer therapy

4 hours ago

New findings about regulation of PD-L1, a protein that allows cancer to evade the immune system, has shown therapeutic promise for several cancers, including the most common form of lung cancer.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.